Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have received an average recommendation of “Buy” from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $30.14.
A number of equities research analysts have issued reports on ABEO shares. Royal Bank of Canada reissued a “buy” rating and set a $26.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, January 24th. SunTrust Banks started coverage on shares of Abeona Therapeutics in a research note on Wednesday, November 8th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $30.00 target price (up previously from $20.00) on shares of Abeona Therapeutics in a research note on Monday, October 16th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Wednesday, November 22nd. Finally, Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, November 20th.
Several hedge funds have recently added to or reduced their stakes in ABEO. Teacher Retirement System of Texas acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at $163,000. Rhumbline Advisers acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $190,000. SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at $218,000. Virtu Financial LLC acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at $246,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $264,000. 41.99% of the stock is owned by institutional investors and hedge funds.
Shares of Abeona Therapeutics (ABEO) traded down $1.47 during trading hours on Friday, hitting $12.60. 2,638,900 shares of the company’s stock were exchanged, compared to its average volume of 1,036,556. The firm has a market cap of $658.36, a price-to-earnings ratio of -18.22 and a beta of 1.23. Abeona Therapeutics has a 52 week low of $4.55 and a 52 week high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. research analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc (ABEO) Receives $30.14 Average Target Price from Brokerages” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/13/abeona-therapeutics-inc-abeo-receives-30-14-average-target-price-from-brokerages.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.